Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 8;2017(1):181-186.
doi: 10.1182/asheducation-2017.1.181.

Chronic neutropenia in LGL leukemia and rheumatoid arthritis

Tal Gazitt  1 , Thomas P Loughran Jr  2
Affiliations
Review

Chronic neutropenia in LGL leukemia and rheumatoid arthritis

Tal Gazitt et al. Hematology Am Soc Hematol Educ Program. .

Abstract

This section reviews the diagnostic criteria and pathogenesis of large granular lymphocyte (LGL) leukemia. There is a particular focus on the overlap of LGL leukemia and rheumatoid arthritis (Felty's syndrome). Current understanding of the mechanisms of neutropenia in these disorders is discussed. Finally, treatment indications and therapeutic recommendations are outlined.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Clinical algorithm for the diagnosis of LGL leukemia. Adapted with permission from Lamy and Loughran.
Figure 2.
Figure 2.
Blood morphology. (A) Small lymphocytes for comparison. (B and C) Typical LGLs on blood smear. Adapted with permission from Lamy and Loughran.
Figure 3.
Figure 3.
Marrow biopsy for immunostaining. Hematoxylin and eosin stain shows slight hypercellularity with compensatory myeloid hyperplasia. CD3 is a pan T-cell marker expressed in all stages of T-cell development. CD8 is a marker for cytotoxic T cells. GzB is a component of cytotoxic granules. CD57 is a marker of terminal differentiation when expressed on CD8+ T cells. Adapted with permission from Lamy and Loughran.
Figure 4.
Figure 4.
Summary of dysregulated cellular pathways in LGL leukemia. Adapted with permission from Lamy et al.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dinmohamed AG, Brink M, Visser O, Jongen-Lavrencic M. Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013. Leukemia. 2016;30(6):1449-1451. - PubMed
    1. Shah MV, Hook CC, Call TG, Go RS. A population-based study of large granular lymphocyte leukemia. Blood Cancer J. 2016;6(8):e455. - PMC - PubMed
    1. Bareau B, Rey J, Hamidou M, et al. . Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534-1541. - PMC - PubMed
    1. Loughran TP, Zickl L, Olson TL, et al. . Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the eastern cooperative oncology group (E5998). Leukemia. 2015;29(4). - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. - PMC - PubMed

MeSH terms

LinkOut - more resources